Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
Date
2018
Journal Title
Journal ISSN
Volume Title
Publisher
Public Library of Science.
Abstract
Abstract available in pdf.
Description
CAPRISA, 2018.
Keywords
Adolescent., Adult., Anti-HIV Agents/adverse effects., Anti-HIV Agents/blood., Anti-HIV Agents/pharmacokinetics.
Citation
Landovitz, R.J., Li, S., Grinsztejn, B., Dawood, H., Liu, A.Y., Magnus, M., Hosseinipour, M.C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M., Hendrix, C.W., Eshleman, S.H., Zhang, Y., Tolley, E., Sugarman, J., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A.R., Margolis, D., Spreen, W.R., Cohen, M.S., McCauley, M.and Eron, J.J. 2018. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Medicine 15(11), e1002690.